Search Results 741-750 of 18373 for alopecia

1. Massage Therapy at Mayo Clinic

   An error occurred, please try again later. Copy for customer care: session ID undefined. Try again. Share · Tweet . VID-20170394.

2. A Study to Test the Addition of berzosertib to Usual Radiation Treatment for Chemotherapy-Resistant Breast Cancer - Mayo Clinic

   Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia ...

3. Safusidenib Phase 2 Study In IDH1 Mutant Glioma - Mayo Clinic

   conditions such as alopecia, temozolomide-induced lymphopenia and irreversible changes associated with radiation therapy). 12. Female patients who engage in ...

4. Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study - Mayo Clinic

   ... alopecia or vitiligo). PRE-REGISTRATION: Hemoglobin >= 9.0 g/dL (obtained =< 28 days prior to pre-registration) (Must be >= 7 days after most recent ...

5. A Study to Evaluate Genetic Testing in Guiding Treatment for Patients with Brain Metastases - Mayo Clinic

   ... alopecia or Grade 2 peripheral neuropathy prior to randomization. A washout period of at least 21 days is required between last chemotherapy dose and ...

6. Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer - Mayo Clinic

   ... alopecia and peripheral sensory neuropathy. - Subjects of childbearing potential agree to use two forms of medically approved contraception while taking the ...

7. Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

   Resolution of all acute toxic effects of prior induction anti-HER2-based chemotherapy regimen to NCI CTCAE version 4.0 Grade ≤1 (except alopecia or other ...

8. Study Evaluating the Safety and Effectiveness of JCARH125 in Subjects with Relapsed and/or Refractory Multiple Myeloma (EVOLVE) - Mayo Clinic

   Recovery to ≤ Grade 1 or baseline of any non-hematological toxicities due to previous therapy, except alopecia and peripheral neuropathy. Females of ...

9. A Study to Evaluate HKI-272 and Capecitabine for HER2-Positive Breast Cancer and Brain Metastases - Mayo Clinic

   ... alopecia). Washout from trastuzumab or hormonal therapy is not required. Participants who are currently receiving any other investigational agents. History ...

10. Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects with Nonresectable or Metastatic IDH1-Mutant Cholangiocarcinoma - Mayo Clinic

    Residual Grade ≤ 2 toxicity from chemotherapy (e.g., alopecia, neuropathy) may be allowed. Major surgery within 4 weeks prior to the first IMP ...